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Abstract. The aim of the present study was to investigate the 
outcomes of esophageal cancer (EC) patients with isolated 
synchronous brain oligometastasis (oligo-BM) treated with 
chemoradiotherapy (CRT) of the primary site and localized 
treatment of the BM with surgery, radiotherapy (RT) or radio-
surgery. Of 125 EC patients investigated, seven patients (6%) had 
solitary BM. Six patients were diagnosed prior to, and one patient 
was diagnosed during, treatment. All patients were treated with 
neoadjuvant chemotherapy and whole-brain RT (WBRT) for 
BM. All but one patient received definitive CRT with a median 
RT dose of 50.4 Gy using conventional fractionation RT. The 
median age at diagnosis was 59 years (range, 48-77 years). Six 
patients succumbed to mortality, and one continued to receive 
systemic chemotherapy at the last visit. The median survival 
time of the patients was 18.9 months (range, 10.0-27.2 months). 
Median time to progression after completion of the treatments 
was 8 months (range, 3-9 months). Two patients had progres-
sion of the primary tumor, and one patient had progression of 
the BM. The neurological status of three patients with BM who 
were identified during the staging work-up did not deteriorate as 
a consequence of WBRT. In conclusion, the present study has 
demonstrated that aggressive treatment of the primary tumor 
and oligo-BM in patients with EC may prolong the survival 
time.
Introduction
Esophageal cancer (EC) is one of the most common tumors 
of the gastrointestinal system. The prognosis of EC patients 
is relatively poor, since the majority of patients are diagnosed 
at an advanced stage. The most common metastatic sites 
include the lungs, liver, and bones (1). The incidence of brain 
oligometastasis (oligo-BM) is extremely rare (1-3% incidence 
in clinical series) (2,3). The majority of patients with BM are 
diagnosed at an advanced clinical stage, and the majority of 
BMs tend to occur together with other organ metastases (2,4,5).
Since brain imaging as part of a metastasis work-up is not 
routinely performed, detection of solitary BM at diagnosis is 
difficult. However, with the increased use of positron emission 
tomography (PET) at initial staging, along with advances in 
neuroimaging, the incidence of BM has gradually increased, 
as reported in the literature (6,7). Due to the rarity of BM 
in patients with EC, there is no standardized treatment for 
these patients. The survival time of patients with EC and 
metastasis to the brain ranges from 2 weeks to 25 months, 
depending on the extent of disease and the treatment modali-
ties employed (7,8). Previously, it was demonstrated that 
patients with one to three BMs had improved survival rates 
with advanced treatment modalities (9). Therefore, an aggres-
sive treatment approach may be effective for only a limited 
number of patients with good performance status and solitary 
metastasis. However, it is important to make balanced clinical 
decisions for treatment planning; specifically, how to identify 
patients with oligometastasis who would benefit from local-
ized therapy. How long localized therapy may be able to extend 
life expectancy has yet to be determined for EC patients with 
BM. In the present study, the long-term survival of seven EC 
patients with isolated synchronous BM treated with definitive 
chemoradiotherapy (CRT) of the primary site, and localized 
treatments such as surgery, radiotherapy (RT) or radiosurgery 
of the BM, is reported.
Patients and methods
Patient population. A retrospective study of the clinical 
records from 125 patients with EC who had been treated 
at Baskent University Faculty of Medicine Department of 
Radiation Oncology, Adana, Turkey, between October 2007 
and December 2015 was designed. Of these 125 patients, 
10 patients (8%) had BM. Seven of the 10 patients (6%) had 
solitary BM diagnosed prior to or during treatment, while three 
patients (2%) had multiple BMs (two patients had multiple BMs 
only, and one patient had BM and lung metastasis). The seven 
patients with a solitary BM were chosen for analysis, and their 
characteristics are summarized in Table I. In these patients, 
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BM was diagnosed via PET, or a combination with computed 
tomography (CT) and magnetic resonance imaging (MRI). In 
addition, three patients received histological confirmation of 
the condition following surgical resection of the brain lesion. 
Written informed consent was obtained from each patient 
prior to inclusion of their data in the present study.
Treatment of primary tumors. Aggressive treatment of the 
primary tumors was performed in three stages. First, seven 
patients with solitary BM were treated with neoadjuvant 
chemotherapy for treatment of the primary tumors (Table I). 
One patient was diagnosed with BM following the second cycle 
of chemotherapy. Three patients received six cycles of cisplatin 
and 5-fluorouracil (5-FU); one patient received six cycles of 
epirubicin, cisplatin, and 5-FU; one patient received six cycles 
of cisplatin and capecitabine; one patient received six cycles 
of 5-FU and folinic acid; and one patient received eight cycles 
of capecitabine. Following completion of the neoadjuvant 
chemotherapy, PET-CT was used for restaging and assessing 
the treatment response (Fig. 1). The primary tumor was 
treated in cases with no progression of the disease following 
systemic chemotherapy. In the second course of treatment, all 
the patients received definitive CRT with a median RT dose 
of 50.4 Gy (range, 50.4-60 Gy) using conventional fraction-
ation with either a 3-dimensional conformal (two patients) or 
intensity-modulated (five patients) RT technique. One patient 
refused additional treatment, and received palliative care only. 
Finally, six of the seven patients underwent a second round 
of chemotherapy: Three patients received 5-FU, two patients 
received capecitabine, and one received cisplatin concurrently 
with RT. All the patients tolerated the treatment well; no 
serious side-effects were observed during or after completion 
of the treatment.
Patients with multiple BMs were treated with palliative 
RT delivered to the primary tumor site after whole-brain 
RT (WBRT), followed by systemic chemotherapy.
Treatment of BMs. Six of seven patients had solitary BM diag-
nosed prior to initiation of any treatment, whereas in one patient, 
BM was identified at the end of the second cycle of chemo-
therapy. Four patients reported headache and nausea/vomiting 
at the first diagnosis, and BM was confirmed using MRI. In 
three patients, no neurological symptoms were observed, and 
BM was identified incidentally by initial PET-CT (Fig. 2). 
Although the treatment regimens of EC patients with BM 
were determined by the treating oncologists, all the patients 
underwent WBRT. Three patients underwent surgical resec-
tion followed by WBRT, and one patient also had Gamma 
Knife radiosurgery prior to WBRT. WBRT was administered 
via a 6 MV linear accelerator in daily fractions of 3 Gy for 
a total dose of 30 Gy delivered in 10 fractions. The Gamma 
Knife radiosurgery dose was 18 Gy, delivered to the solitary 
metastasis. All the patients tolerated the treatment well; only 
corticosteroids were administered during the RT, if required.
Results
Patient outcomes for patients with solitary BM. The median 
age for the seven patients at diagnosis was 59 years (range, 
48-77 years). All the patients were male, and six succumbed 
to mortality resulting from their cancer (Table II). The 
median survival time of the patients was 18.9 months 
(range, 10.0-27.2 months). The median time to progression 
after completion of all the treatments was 8 months (range, 
3-9 months). Two patients had tumor progression at the 
primary site, and one patient had BM progression. Two patients 
with localized progression of the primary tumor also had 
intra-abdominal lymph node metastasis, which was observed 
3 and 9 months, respectively, following completion of the 
treatment. These patients received systemic chemotherapy: 
One patient succumbed to the cancer as a consequence of 
disease progression, whereas the other patient remained alive, 
although with the disease (Table II). The patient who had 
progression of the BM was treated with excision of the BM, 
followed by WBRT. Eight months following completion of the 
treatment, new metastatic foci in the brain and lung were iden-
tified (Fig. 3). Evidence of systemic progression was observed 
at multiple sites, although mostly in the liver and lungs. Two 
patients with adenocarcinoma had liver metastasis only at 5 
and 9 months, respectively, after the completion of treatment. 
Table I. Characteristics of EC patients with solitary BM.
Patient     Treatment Treatment Systemic
no. Age, sex Diagnosis Stage Location (esophagus) (BM) treatment
1 50, M Adeno Ca T4N1 Distal 1/3 CRT (54 Gy + capecitabine) WBRT 6 x cisplatin 
       + capecitabine
2 48, M Adeno Ca T3N1 Distal 1/3 CRT (54 Gy + 5-FU) Surgery + WBRT 6 x CFF
3 48, M Adeno Ca T3N1 Distal 1/3 CRT (60 Gy+ 5-FU)  GK + WBRT 6 x ECF
4 76, M Adeno Ca T4N0 Distal 1/3 CRT (50.4 Gy + 5-FU) Surgery + WBRT 6 x FU-FA
5 59, M SCC T4N1 Mid 1/3 CRT (60 Gy + cisplatin) Surgery + WBRT 6 x CFF
6 77, M Adeno Ca T3N1 Distal 1/3 CRT (54 Gy + capecitabine) WBRT 8 x capecitabine
7 69, M SCC T3N0 Proximal 1/3 RT (60 Gy) WBRT 6 x CFF
EC, esophageal cancer; BM, brain metastasis; M, male; Adeno Ca, adenocarcinoma; SCC, squamous cell carcinoma; CRT, chemoradiotherapy; 
5-FU, 5-fluorouracil; RT, radiotherapy; WBRT, whole-brain radiotherapy; GK, Gamma Knife; CFF, cisplatin/5-fluorouracil/folinic acid, ECF, 
epirubicin/cisplatin/5-fluorouracil; FA, folinic acid.
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One patient had liver metastasis, together with lung metastasis 
and BM 9 months after completion of the treatment. One 
patient refused systemic chemotherapy, and succumbed from 
the disease under supportive care.
Figure 1. PET-CT was used for restaging and assessing the treatment response after completion of neoadjuvant chemotherapy. FDG-PET/CT images of patient 
no. 4 are shown. (A) Increased FDG uptake at the distal esophagus and gastroesophageal junction [maximum standardized uptake value (SUVmax) = 15.6 
prior to initiation of the treatment]. (B) Marked response observed following six cycles of 5-fluorouracil and folinic acid treatment. PET, positron emission 
tomography; CT, computed tomography; FDG, 18F-fluorodeoxyglucose.
Figure 2. A representative patient, where BM was identified incidentally by initial PET-CT. FDG-PET/CT images of patient no. 6. (A) FDG-PET image, 
demonstrating increased uptake in the brain (arrow), and distal esophagus (arrow) indicating the presence of the primary tumor and BM. (B and C) Overlaid 
PET and CT images, demonstrating increased FDG uptake in the the parietal region of the brain [maximum standardized uptake value (SUVmax) = 11.6] and 
distal esophagus (SUVmax = 12.4). BM, brain metastasis; PET, positron emission tomography; CT, computed tomography; FDG, 18F-fluorodeoxyglucose.
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Neurological symptoms at diagnosis in four patients were 
resolved completely after the conclusion of WBRT. Mild to 
moderate headache, which was resolved following corticoste-
roid administration, was observed during RT. The neurological 
status of three patients with BM that had been identified 
incidentally during staging work-up did not deteriorate after 
WBRT.
Outcomes for patients with multiple BMs. Two patients with 
multiple BMs, who were provided palliative treatment, only 
survived 2.1 and 3.1 months after the diagnosis. One of these 
patients only had BM, whereas the other patient had liver 
metastasis together with BM.
Six patients were diagnosed with multiple BMs at a 
median of 2.5 months (range 0.8-16.2 months) following 
completion of the primary tumor treatment. Three of six 
patients had BM only, while one patient had local recur-
rence, one patient had liver metastasis, and one patient had 
lung and liver metastasis, together with multiple BMs. The 
median survival of patients with BM observed after comple-
tion of the curative treatment of EC was 5.0 months (range, 
1.0-9.6 months).
Discussion
In the present patient series, the efficacy of treatment of both 
BM and primary tumor in EC patients with synchronous 
solitary BM was investigated, and longer survival times were 
observed.
BM from EC is extremely rare, and only limited informa-
tion is available. In the literature, the incidence of BM was 
0-2% in clinical studies, and 0-5.1% in autopsy studies (3,4). 
Kanemoto et al (10) reported that the crude and 3-year cumula-
tive incidences of BM in 391 patients with EC following CRT 
were 3.1 and 6.6%, respectively. However, in the majority of 
studies, the incidence of BM has probably been underestimated 
since, in most series, routine brain imaging is not typically part 
of the metastatic work-up. In the current study, the incidence 
of BM was 6%, which was slightly higher compared with 
previously published series (3-6). Although patients with BM 
were not routinely evaluated with MRI in the present study, in 
four patients with neurological symptoms, cranial CT or MRI 
was performed to rule out BM. Furthermore, the majority of 
patients with EC were evaluated with 18F-fluorodeoxyglucose 
(FDG)-PET/CT for initial staging and RT planning. In three 
Figure 3. Magnetic resonance images of patient no. 2, demonstrating new metastatic foci and progression of primary metastatic lesions, observed 8 months 
after completion of all the treatments.
Table II. Treatment outcomes for EC patients with BM. 
   Time to progression Overall survival time
Patient no. Progression site Status (months) (months)
1 Esophagus, intra-abdominal ln DwD 3 10.0
2 Lung, brain DwD 8 20.3
3 Liver DwD 5 20.6
4 Liver DwD 9 27.2
5 Lung DwD 5 13.9
6 Esophagus, intra-abdominal ln AwD 9 14.5
7 Lung, liver, bones DwD 9 18.9
EC, esophageal cancer; BM, brain metastasis; ln, lymph node; DwD, died with disease; AwD, alive with the disease.
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patients, the existence of BM was demonstrated incidentally 
with FDG-PET/CT, although these patients did not have 
any neurological symptoms. Since it was reported that the 
sensitivity of PET-CT for detecting BM in other cancer types 
was 70%, and the specificity was very high (11), the higher 
incidence of BM in the current study may be connected with 
higher rates of PET-CT use compared with previous studies.
There have been several efforts to assess whether neuro 
staging is essential for patients with EC. Gabrielsen et al (8) 
explored the usefulness of preoperative cranial CT to inves-
tigate occult metastases in a cohort of 240 patients who 
underwent esophagectomy. However, none of the patients were 
found to have occult metastases by CT. The authors suggested 
that a consistent, true incidence of BM from EC in their 
material could not be determined exactly by CT, and that the 
crude incidence of BM was 3.6% if MRI were to have been 
used instead of CT. Studies detecting BM in routine staging 
are very rare; the majority of studies involved lung cancer 
patients (12,13). In a study by Seute et al (12), the incidence 
of BM in 481 patients with small cell lung cancer was 10% 
with CT, but increased up to 24% with MRI. Furthermore, 
in the CT group, all the patients diagnosed with BM were 
symptomatic, whereas in the MRI group, 11% of the patients 
were symptomatic. These authors concluded that the estimated 
incidence of BM increased when MRI was used instead of CT. 
Hjorthaug et al (13) assessed whether PET-CT was suitable for 
selecting patients for MRI on suspicion of BM in 596 patients 
with lung cancer. The sensitivity, specificity, and positive 
predictive values were 72, 100, and 97%, respectively, and the 
authors concluded that PET-CT may be suitable for selecting 
patients for MRI in diagnostic centers that did not perform 
routine MRI in the pre-therapeutic staging work-up. The 
results of the present study also supported this finding: Higher 
rates of oligo-BM were detected at the time of EC diagnosis, 
which could have been due to the routine use of FDG-PET/CT 
for initial staging for the majority of the cases.
The stage of the primary tumor is the most important 
risk factor for survival of patients with EC (2). Similarly, BM 
tended to occur in patients with advanced clinical disease (4), 
which was supported by the present series. In the current 
study, all the patients had clinical-stage T3 or T4 disease, and 
five of seven patients also had clinical lymph node metastasis. 
Another risk factor for predicting BM in patients with EC is 
mean tumor length. It was previously reported that primary 
tumor length in EC patients without BM was shorter compared 
with EC patients with BM (4,8). In addition, treatment modality 
influences the time to BM development. Song et al (4) demon-
strated that the median time to BM development was longer 
in patients treated with CRT compared with patients treated 
with chemotherapy alone (15.2 vs. 7.6 months). These findings 
indicated that patients with an extensive clinical stage have 
a high risk for developing BM, and treatment of the primary 
tumor with definitive CRT may extend the time prior to BM 
occurrence. In the current study, another factor contributing 
towards longer survival time was connected with successful 
local treatment with definitive CRT. Only two patients had 
local recurrence, together with intra-abdominal lymph node 
metastasis.
The prognosis is poor for EC patients with BM, and only 
limited data are available concerning treatment approaches. 
The median survival time after diagnosis of BM was only 
3.8 months, according to a report by Weinberg et al (5). 
However, it was reported in certain series that surgical resec-
tion of isolated BM in EC patients, with or without WBRT, 
resulted in a 3.8-26.2 month median survival time (2,5,14). 
In the largest series reported by Ogawa et al (2), the mean 
survival time was 1.8 months in patients treated with WBRT 
alone, 3.8 months in patients who underwent surgical resection 
of a solitary BM, and 9.6 months in patients with EC treated 
with WBRT following surgical resection of a solitary BM. 
However, 5 of 36 patients who underwent postoperative WBRT, 
and who had no active extracranial disease, survived >1 year. 
Weinberg et al (5) demonstrated in a study of 27 patients that 
the longest survival time was observed in patients with single 
BM who underwent surgery and WBRT (median survival, 
9.6 months), WBRT alone, surgery, surgery and WBRT, or 
stereotactic radiosurgery (SRS) alone. Yoshida (14) evalu-
ated the treatment outcomes of patients with BM treated with 
WBRT alone, surgery alone, and postoperative WBRT. The 
median survival time of patients with single BM treated with 
SRS was 38.2 months, compared with 16.4 months for patients 
with multiple BMs. The author concluded that the best outcome 
was observed in patients treated with surgical resection 
followed by RT. Song et al (4) reported a median survival time 
of 4.2 months for 26 patients with BM (12 with single BM, and 
14 with multiple BMs); the longest survival time was 7 months 
in patients who underwent surgery and postoperative RT. In 
the present series, although patients treated with postoperative 
WBRT or SRS and WBRT survived slightly longer compared 
with patients treated with WBRT alone, the progression of BM 
was observed only in one patient treated with postoperative 
WBRT. However, patients with multiple BMs at diagnosis who 
were provided palliative treatment only had very low survival 
rates, which may have been due to disease dissemination.
The kinetics of development of micrometastases, and 
particularly of oligometastases, was explored after having made 
certain assumptions. It is accepted that, beyond a threshold for 
the initiation of metastatic spread, which varies widely among 
different tumor types, the rate of primary tumor deposits with 
metastatic potential increases exponentially (15). Therefore, 
the delivery of metastatic clonogens from the primary tumor is 
accompanied by a similar exponential growth of each micro-
metastasis that becomes newly established at another site. The 
aim of treatment of oligometastatic disease has the potential 
to prevent further evolution of genetically unstable clones 
and metastatic spread, which may potentially improve overall 
disease control (16,17). Multiple trials are under way to deter-
mine whether localized treatment of oligometastatic disease 
has been beneficial in various types of cancers; however, no 
data on EC patients with BM are available in the literature.
The present study had several limitations. First, this was 
a retrospective study. Secondly, the patient number was rela-
tively limited, and therefore it was difficult to draw strong 
conclusions. Thirdly, there may have been patient selection 
bias: Although patients with single BM were analyzed who 
had an improved performance status, in the current study, 
patients with multiple BMs had a worse performance status 
and disseminated disease. Therefore, it was not possible 
perform a head-to-head comparison. Patients with multiple 
BMs who exhibited a good treatment response should also be 
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evaluated. Finally, patients who received different treatment 
regimens were included in the analysis, which might have 
affected treatment outcomes. In the present series, cases were 
selected according to an approximately similar treatment 
strategy, which was neoadjuvant chemotherapy with treatment 
of BM at diagnosis, followed by definitive CRT or RT of the 
primary tumor site, even in cases where a good treatment 
response was observed.
Nevertheless, the present study has produced a number of 
important findings. Improved survival times were observed in 
selected patients treated with aggressive systemic and local 
treatment modalities. In addition, patients with oligometastasis 
are an important population, and the survival time of this 
population may be extended with appropriate diagnostic and 
treatment modalities.
In conclusion, the present study is, to the best of our knowl-
edge, the first to demonstrate the efficacy of aggressive local 
and systemic treatment of the primary tumor site and BM of 
patients with EC. Although the prognosis of EC with BM is 
relatively poor, the findings in this study have revealed that the 
long-term survival of EC patients with BM may be augmented 
by locally ablative treatment of the primary tumor and the 
BM. Therefore, in selected patients, a curative approach with 
effective concurrent CRT, rather than palliative treatment, 
may result in improved local control and prolonged survival 
rates. With novel targeted therapeutics and effective adjuvant 
systemic therapies to control systemic disease, longer survival 
rates may be observed in selected EC patients with BM. 
Finally, physicians should be aware of the metastatic status of 
such patients prior to their deciding upon a treatment plan.
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